Who makes Preserved latanoprost 0.005%?

Preserved latanoprost 0.005% is developed by Medical University of Vienna.

What development phase is Preserved latanoprost 0.005% in?

Preserved latanoprost 0.005% is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Preserved latanoprost 0.005%

Medical University of Vienna · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Preserved latanoprost 0.005%
Sponsor	Medical University of Vienna
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison of Preserved and Preservative-free Latanoprost 0.005% in Primary Open Angle Glaucoma and Ocular Hypertensive Patients, at Guinness Eye Centre, Lagos. (PHASE4)
Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT (PHASE4)
Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients (PHASE3)
Ocular Signs and Symptoms in Glaucoma Patients Switched From Latanoprost to Preservative Free Tafluprost Eye Drops (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Preserved latanoprost 0.005% CI brief — competitive landscape report
Preserved latanoprost 0.005% updates RSS · CI watch RSS
Medical University of Vienna portfolio CI